Dimensional Fund Advisors LP boosted its position in shares of Seres Therapeutics Inc (NASDAQ:MCRB) by 45.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,600 shares of the biotechnology company’s stock after buying an additional 11,488 shares during the period. Dimensional Fund Advisors LP owned 0.09% of Seres Therapeutics worth $414,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MCRB. Geode Capital Management LLC boosted its position in Seres Therapeutics by 5.8% during the first quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after purchasing an additional 9,060 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 24.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock valued at $501,000 after acquiring an additional 8,851 shares in the last quarter. Northern Trust Corp lifted its position in shares of Seres Therapeutics by 16.2% in the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after acquiring an additional 32,875 shares in the last quarter. Citadel Advisors LLC lifted its position in shares of Seres Therapeutics by 94.6% in the second quarter. Citadel Advisors LLC now owns 40,212 shares of the biotechnology company’s stock valued at $455,000 after acquiring an additional 19,550 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Seres Therapeutics in the second quarter valued at $236,000. 77.83% of the stock is currently owned by institutional investors.
MCRB has been the subject of several analyst reports. Zacks Investment Research lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Citigroup assumed coverage on Seres Therapeutics in a research note on Thursday, October 12th. They issued a “positive” rating and a $19.00 target price for the company. CIBC assumed coverage on Seres Therapeutics in a research note on Friday, October 13th. They issued an “outperform” rating and a $19.00 target price for the company. Oppenheimer began coverage on Seres Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $19.00 target price for the company. Finally, Seaport Global Securities reissued a “buy” rating and issued a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.00.
Shares of Seres Therapeutics Inc (NASDAQ MCRB) opened at $9.84 on Friday. Seres Therapeutics Inc has a 1 year low of $8.85 and a 1 year high of $17.42. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53.
Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The firm had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $17.29 million. During the same period last year, the firm earned ($0.46) EPS. The firm’s revenue was up 76.9% compared to the same quarter last year. sell-side analysts predict that Seres Therapeutics Inc will post -2.24 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics Inc (MCRB) Stake Increased by Dimensional Fund Advisors LP” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/15/seres-therapeutics-inc-mcrb-stake-boosted-by-dimensional-fund-advisors-lp.html.
Seres Therapeutics Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.